Abstract：Objective To explore the effect of Tirofiban application at different time on the patients with acute ST segment elevation myocardial infarction (STEMI) in PCI. Methods From February 2013 to May 2016, in Department of Emergency, Beijing Shijingshan Hospital, 200 patients with acute STEMI and accepted PCI treatment were selected, according the application time of Tirofiban, they were divided into the group A (95 cases, given Tirofiban after entering the resuscitation room immediately), group B (56 cases, given Tirofiban application at the end of the emergency after coronary angiography,) control group (49 cases, without Tirofiban). The therapeutic effect and safety the three groups were evaluated and compared. Results There were no significant differences in the aspects of TIMI flow grade and myocardial perfusion grade among the three groups before the PCI (P > 0.05). After PCI, there were no significant differences in the aspect of TIMI flow grade among the three groups (P > 0.05), but group A, group B were better than control group in TIMI myocardial perfusion grade， the differences were statistically significant (P < 0.05), there was no significant difference between group A and group B (P > 0.05). Before PCI, CK-MB, cTNT in three groups were copmpared, the differences were not statistically significant (P > 0.05). After PCI, CK-MB, cTNT in group A, group B were lower than control group, the differences were statistically significant (P < 0.05). Before PCI, NT-proBNP and cardiac function in three groups were compared, the differences were not statistically significant (P > 0.05). After PIC, NT-proBNP, LVEDD and LVESD in group A, group B were lower than control group, LVEF was higher than control group, the differences were not statistically significant (P > 0.05). Three patients were followed up for 6 months, occurrence rate of hemorrhage and thrombocytopenia, MACE of three groups were compared, the differences were not statistically significant (P > 0.05). Conclusion Application of tirofiban in STEMI patients with emergency PCI treatment can effectively improve blood flow and myocardial perfusion, decrease myocardial damage, and the earlier application, the effect is more significant, the adverse reactions were tolerable, it is worthy of promotion.
张楠. 替罗非班在急性ST段抬高型心肌梗死行PCI术患者中应用的最佳时机[J]. 中国医药导报, 2018, 15(8): 124-128.
ZHANG Nan. Analysis of the best application time of Tirofiban on patients with acute ST segment elevation myocardial infarction undergoing PCI. 中国医药导报, 2018, 15(8): 124-128.
2018, Vol. 15 
京公网安备 11010502046598号